Abstract
OBJECTIVE: To provide references for the selection of an appropriate statin and its dose adjustment in clinical practice when combined lopinavir/ritonavir (LPV/r) and statins. METHODS: Pharmacokinetic interactions between LPV/r and seven commonly used statins were reviewed by searching relevant domestic and foreign literatures. RESULTS AND CONCLUSIONS: Ritonavir is a potent time dependent inhibitor of cytochrome P450 3A4 (CYP3A4) and will greatly increase the plasma exposure of simvastatin and lovastatin, leading to the increasing risk of liver damage and rhabdomyolysis. Therefore, it is forbidden to use LPV/r together with these two statins. Whereas atorvastatin and rosuvastatin need to be used with caution and started at the lowest dose. No clinical data has been reported to support the relationship and extent of fluvastatin and LPV/r interactions, nor is there a dose recommendation for the combination. Moreover, LPV/r almost have no effect on the pharmacokinetic profiles of pravastatin and pitavastatin, so it is recommended to use pravastatin/pitavastatin with LPV/r in clinical practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
